Alcon Research, LLC announced on March 24, 2025, an agreement to acquire LENSAR, Inc. in a transaction that could be worth up to $430 million. Under the terms of the agreement, LENSAR shareholders will receive $14.00 per share in cash.
Shareholders are also eligible for an additional non-tradeable contingent value right (CVR) of up to $2.75 per share in cash. This CVR is conditioned on the achievement of 614,000 cumulative procedures with LENSAR’s products between January 1, 2026, and December 31, 2027.
The acquisition includes LENSAR's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software, and its legacy laser system. The deal is expected to close in mid-to-late 2025, subject to regulatory approvals and LENSAR's shareholder approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.